Invesco Ltd. Viridian Therapeutics, Inc.\De Transaction History

Invesco Ltd.

$499 Billion
Q3 2024

A detailed history of Invesco Ltd. transactions in Viridian Therapeutics, Inc.\De stock. As of the latest transaction made, Invesco Ltd. holds 20,749 shares of VRDN stock, worth $419,129. This represents 0.0% of its overall portfolio holdings.

Number of Shares

20,749

Previous 20,571 0.87%

Holding current value

$419,129

Previous $267,000 76.78%

% of portfolio

0.0%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$12.16 - $23.33 $2,164 - $4,152	178 Added 0.87%	20,749 $472,000
Q2 2024 Aug 13, 2024	BUY	$11.6 - $17.26 $21,355 - $31,775	1,841 Added 9.83%	20,571 $267,000
Q1 2024 May 14, 2024	SELL	$17.09 - $23.82 $2.15 Million - $3 Million	-126,035 Reduced 87.06%	18,730 $327,000
Q4 2023 Feb 12, 2024	BUY	$11.12 - $22.5 $1.3 Million - $2.63 Million	116,932 Added 420.12%	144,765 $3.15 Million
Q3 2023 Nov 13, 2023	BUY	$15.16 - $24.7 $127,253 - $207,331	8,394 Added 43.18%	27,833 $426,000
Q2 2023 Aug 11, 2023	BUY	$22.57 - $29.67 $17,807 - $23,409	789 Added 4.23%	19,439 $462,000
Q1 2023 May 12, 2023	SELL	$25.04 - $37.6 $4.4 Million - $6.61 Million	-175,887 Reduced 90.41%	18,650 $474,000
Q4 2022 Feb 13, 2023	SELL	$18.78 - $29.74 $559,249 - $885,627	-29,779 Reduced 13.28%	194,537 $5.68 Million
Q3 2022 Nov 14, 2022	BUY	$10.7 - $25.5 $2.28 Million - $5.44 Million	213,278 Added 1932.22%	224,316 $4.6 Million
Q2 2022 Aug 15, 2022	BUY	$9.55 - $19.0 $105,412 - $209,722	11,038 New	11,038 $128,000

Others Institutions Holding VRDN

# of Institutions

179

Shares Held

76.8M

Call Options Held

581K

Put Options Held

439K

View Full List

About Viridian Therapeutics, Inc.\DE

Ticker VRDN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,888,900
Market Cap $806M
Description
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...

More about VRDN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Invesco Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Invesco Ltd. with notifications on news.

Account